Royalty Report: Medical, Device, Diagnostic – Collection: 5729

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Medical
  • Device
  • Diagnostic
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5729

License Grant
LICENSEE hereby grants back to LICENSOR the co-exclusive rights under the license granted to LICENSEE.

LICENSEE is granted an exclusive worldwide license to certain patent rights and know how relating to the determination of glucose concentration in body fluid which glucose is obtained using ultrasonic techniques.

LICENSOR will have worldwide coexclusive rights to develop and market LICENSOR's continuous transdermal glucose monitoring system using the SonoPrep ultrasonic skin permeation technology for the hospital intensive care unit (ICU) market.

License Property
Licensor Patent Rights

1

US 6,234,990 B2

US 6,234,990 B1

WO 9800194 A2

EP 0925088 A2

2

WO 0170330 A2

EP 1225831 A2

3

U.S. 6,190,315 B1

WO 99348578 A1

EP 1045714 A1

4

WO 0035357 A1

EP 1139886 A1

5

WO 0035351 A

Field of Use
Field of Use shall mean the area of determination of glucose concentration in body fluid which glucose is obtained using ultrasonic techniques.

IPSCIO Record ID: 25894

License Grant
Licensor hereby grants to Licensee an exclusive worldwide right and license under the Patent Rights and Know-How in the Field of Use, with the right to grant sublicenses, to make, have made, use, import, and sell any Licensed Products and/or Processes during the term hereof.   Licensors intellectual property relates to continuous transdermal glucose monitoring system utilizing ultrasonic techniques.
License Property
It has completed the first prototypes of its continuous glucose monitor using proprietary ultrasonic skin permeation technology for the hospital intensive care unit (ICU), and expects to begin human clinical studies in early 2006.

Licensor Patent Rights

1

US 6,234,990 B2

US 6,234,990 B1

WO 9800194 A2

EP 0925088 A2

2

WO 0170330 A2

EP 1225831 A2

3

U.S. 6,190,315 B1

WO 99348578 A1

EP 1045714 A1

4

WO 0035357 A1

EP 1139886 A1

5

WO 0035351 A

Field of Use
Field of Use shall mean the area of determination of glucose concentration in body fluid which glucose is obtained using ultrasonic techniques.

IPSCIO Record ID: 6495

License Grant
The Licensor entered into a Collaboration Agreement with the Licensee. Pursuant to the Agreement, the Licensor and the Licensee agreed to develop jointly and to market an in-hospital continuous blood glucose monitoring system. The Agreement provides the Licensee with an exclusive License under the Company’s intellectual property in the hospital market. The Licensee will be responsible for global sales and marketing, and the Licensor will initially be responsible for manufacturing.
License Property
The automatic glucose monitoring system is indicated for automatic, real-time monitoring and trending of blood glucose concentration in critically ill adults in the hospital environment.  The development of a method for continuous glucose monitoring via an indwelling sensor would enable clinicians to be more effective in implementing tight glycemic control and provide for better accuracy in monitoring and controlling patients' blood glucose levels.
Field of Use
The rights granted relate in the hospital market. Specifically for use in the critical care market.

IPSCIO Record ID: 1804

License Grant
The Company hereby grants the worldwide right to manufacture, cause to be manufactured, promote, sell, market, distribute and use the Pump Technology; programmable implantable insulin pump system.
License Property
Implantable microinfusion pump systems intended for in vivo use; utilizes Pump Technology for diabetes or non-diabetes applications. Glucose Controllers, Glucose Monitors, Long-Term Glucose Sensors and the abdominal lead that connects the implantable pump to a Long-Term Glucose Sensor are not Licensed Products.  An apparatus or system which utilizes Glucose Sensing Technology to control an insulin infusion device in a human or in an animal.   Any monitor product utilizing Glucose Sensing Technology to provide indications of glucose concentration or changes in glucose concentration in a human or in an animal.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.